Christina Ravera
Overview
Explore the profile of Christina Ravera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spencer A, Roberts A, Kennedy N, Ravera C, Cremers S, Bilic S, et al.
BMC Clin Pharmacol
. 2008 Apr;
8:2.
PMID: 18377658
Background: Cases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety study of...
2.
Hoekstra R, Dumez H, Eskens F, van der Gaast A, Planting A, de Heus G, et al.
Clin Cancer Res
. 2005 Oct;
11(19 Pt 1):6908-15.
PMID: 16203782
Purpose: This phase I study was conducted to assess the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor tyrosine kinase inhibitor PKI166 in patients with...
3.
Skerjanec A, Berenson J, Hsu C, Major P, Miller Jr W, Ravera C, et al.
J Clin Pharmacol
. 2003 Mar;
43(2):154-62.
PMID: 12616668
An open-label pharmacokinetic and pharmacodynamic study of zoledronic acid (Zometa) was performed in 19 cancer patients with bone metastases and known, varying levels of renal function. Patients were stratified according...
4.
Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al.
J Clin Pharmacol
. 2002 Nov;
42(11):1228-36.
PMID: 12412821
The pharmacokinetics, pharmacodynamics, and safety of zoledronic acid (Zometa), a new-generation bisphosphonate, were evaluated in 36 patients with cancer and bone metastases. Zoledronic acid (by specific radioimmunoassay) and markers of...
5.
Legay F, Gauron S, Deckert F, Gosset G, Pfaar U, Ravera C, et al.
J Pharm Biomed Anal
. 2002 Nov;
30(4):897-911.
PMID: 12408879
Zoledronic acid is a new, highly potent bisphosphonate drug under clinical evaluation. A radioimmunoassay has been developed to determine zoledronic acid concentration in human serum, plasma, and urine. The assay...